Aripiprazole Long Acting and Clozapine: Between Efficacy and Tolerability
Clinical Neuropsychopharmacology and Addiction · 2026
DOI: 10.53941/cna.2026.100004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neuropsychopharmacology and Addiction, 2026. Verfasst von Luca Persico und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients affected by schizophrenia often experience a poor quality of life. Antipsychotics currently used reduce treatment compliance because of their side effects and their high non-responder rate. Antipsychotic polytherapy, also with Long-acting injectables (LAI) formulation, may increase the efficacy in refractory and non-compliant patients. This systematic review examines the coadministration of clozapine and aripiprazole LAI, studying its efficacy, tolerability and side-effects.
Methods
The research was conducted on 6 August 2025, using PubMed, Scopus and Web of Science. The query search tool used was “aripiprazole AND clozapine AND (Long acting OR injectable OR LAI OR combination)”. Only original papers written in English were considered; animal research, in vitro experiments, also studies not specifying the formulation of aripiprazole were excluded.
Results
Our research produced 1637 records. Removing repeated, not written in English and off topic articles, six papers were selected for qualitative synthesis.
Conclusions
Available evidence on the combined use of clozapine and long-acting injectable aripiprazole is limited and largely derived from small observational studies. The reviewed reports describe recurring clinical observations suggesting that this strategy may be applicable in selected patients with treatment-resistant schizophrenia, particularly in the presence of poor adherence or clozapine-related tolerability concerns. Reported outcomes include symptom stabilization, improved adherence, and possible benefits on residual symptoms and clozapine-related adverse effects. Nonetheless, the low certainty of the evidence prevents firm conclusions regarding efficacy and safety, highlighting the need for further prospective controlled studies.
Zitieren
APA
Persico, L., Sante, L. D., Xynelis, M., Miuli, A., Mosca, A., & Pettorruso, M. (2026). Aripiprazole Long Acting and Clozapine: Between Efficacy and Tolerability. Clinical Neuropsychopharmacology and Addiction. https://doi.org/10.53941/cna.2026.100004
Vancouver
Persico L, Sante LD, Xynelis M, Miuli A, Mosca A, Pettorruso M. Aripiprazole Long Acting and Clozapine: Between Efficacy and Tolerability. Clinical Neuropsychopharmacology and Addiction. 2026. doi:10.53941/cna.2026.100004
BibTeX
@article{Persico2026,
author = {Persico, Luca and Sante, Ludovica Di and Xynelis, Michele and Miuli, Andrea and Mosca, Alessio and Pettorruso, Mauro},
title = {Aripiprazole Long Acting and Clozapine: Between Efficacy and Tolerability},
journal = {Clinical Neuropsychopharmacology and Addiction},
year = {2026},
doi = {10.53941/cna.2026.100004}
}
EUVIMED